Archives for the 'Member Spotlight' Category
SyntheMed’s REPEL-CV Now Available in Canada
REPEL-CV, SyntheMed’s bioresorbable adhesion barrier film used following cardiac surgery, has received Health Canada approval for use in pediatric patients who undergo open heart procedures. The product will be marketed by Force3 Medicale, a Montreal-based distributor of cardiac surgery products.
SyntheMed was previously granted CE Mark approval to market REPEL-CV in most international markets; the […]
Timothy Sullivan Honored by Medical Device & Diagnostic Industry Magazine
Timothy Sullivan, President and CEO of Mystic Pharmaceuticals, has been recognized by the editors of Medical Device & Diagnostic Industry as one of the magazine’s 100 notable people in the device industry.
Sullivan, along with John Bradley, founded Mystic Pharmaceuticals in 2003. He’s the man behind Mystic’s VersiDoser platform, an aseptic unit dose drug packaging and […]
Chembio to Screen Teens with HIV Rapid Tests
Chembio Diagnostics has completed a clinical study evaluating the performance of its two FDA approved rapid HIV tests in teens 13-17 years old. The objective of the clinical study, detecting HIV antibodies in this patient population, was successfully achieved.
Pending a review by the FDA, Chembio will extend the availability of its HIV tests to this […]
CryoLife-BioForm Eye Browplasties
BioGlue is now available for use in browlift cosmetic and plastic surgery in the EU.
CryoLife, maker of BioGlue, has had its eyes set on the lucrative plastic surgery market since at least 2006 when they partnered with BioForm, a privately-held medical device firm headquartered in San Mateo, CA.
Under the terms of that agreement, CryoLife became […]
NovaDel Partners with BioAlliance Pharma SA to Bring Ondansetron Oral Spray to Market
NovaDel has entered into a collaboration agreement with BioAlliance Pharma SA for the development and commercialization of NovaDel’s ondansetron oral spray (OS) for Europe. Ondansetron is a 5-HT3 antagonist to prevent nausea and vomiting after chemotherapy, radiation and surgery. Upon successful development and approval, NovaDel believes ondansetron OS could be the first antiemetic to be […]
NovaDel Announces $4 Million Financing
NovaDel entered into a private placement for up to $4 million, in the form of secured convertible promissory notes with an interest rate of 10% and warrants to purchase shares of the company’s common stock.
NovaDel intends to close on approximately $1.5 million in the initial closing upon AMEX approval and customary closing conditions. The balance […]
[Video Profile] Interview with Ralph Makar, President & CEO of Bioject Medical
Bioject Medical develops and markets needle-free injection technology used to administer injectable medications.
Bioject’s technology works by forcing liquid medication at high speed through a tiny orifice (smaller than a human hair) held against the skin. This creates an ultra-fine stream of fluid that penetrates the skin in a fraction of a second. Several studies have […]
CryoLife on Firm Footing: EPS Increases, Revenues Up, Raises Guidance
Revenues at CryoLife rose 4% to $25.6 million in the first quarter of 2008. Net income was $2.8 million, or $0.10 per share, compared to $1.4 million, or $0.04 per share in Q1 2007.
Tissue processing revenues in Q1 2008 increased 4% to $13.4 million, primarily due to increased demand for the company’s cardiac and vascular […]
CryoLife to Distribute Medafor Hemostatic Agent
CryoLife, in a three-year agreement signed last week, will become the exclusive U.S. distributor of Minneapolis, MN-based Medafor’s microporous polysaccharide hemostatic (MPH) agent for use in cardiac and vascular surgeries.
CryoLife will also offer MPH outside of the U.S. (excluding Japan and China) in cardiac, vascular and general surgical procedures but not in orthopedic or ENT […]
Cancer Researchers See the Light: Caliper Life Sciences Intruduces Bioware Ultra
Five cancer cells were injected subcutaneously into the dorsal region near the thigh of mouse. Tumor growth is monitored weekly by an IVIS Spectrum. The tumor was visible 28 days post implantation; Bioluminescent signal could be detected in the animal long before it could be measured with a caliper.
By tagging a tumor with the gene […]
